Liquidia Corporation Provides Update on New Drug Application for Yutrepia (treprostinil) inhalation powder

MORRISVILLE, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) provided an update on its review of the New Drug Application (NDA) for...

https://www.drugs.com/nda/yutrepia_240125.html

Source: Drugs.com - New Drug Applications - January 25, 2024 Category: Drugs & Pharmacology Source Type: news

More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | New Drug Applications